Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YL 17231

Next Previous
Drug Profile

YL 17231

Alternative Names: Pan-KRAS Inhibitor YL-17231; TEB-17231; YL-17231

Latest Information Update: 05 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Yingli Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 31 Oct 2023 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease) in USA (PO) (NCT06096974)
  • 28 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT06078800)
  • 07 Jul 2023 280Bio plans a phase I trial for Cancer (Late-stage disease) in the US in the fourth quarter of 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top